Denali Advisors’s ARS Pharmaceuticals SPRY Stock Holding History

Denali Advisors’s Portfolio SPRY Stock Details SPRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-87,500	Closed	-$480K	–	498
2023 Q4	$480K	Buy	+87,500	New	+$383K	0.15%	145

Other funds holding SPRY

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KPF

K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Denali Advisors's SPRY Position: Q1 2024 in Review

Denali Advisors sold out of ARS Pharmaceuticals (SPRY) in Q1 2024, closing a stake of 87,500 shares — an estimated $480K sold.

Denali Advisors first reported a position in SPRY in Q4 2023 and held it in 1 quarter. The position peaked at $480K in Q4 2023. 113 funds tracked by Wall St. Rank hold SPRY as of Q1 2024.

Denali Advisors reported no remaining ARS Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Denali Advisors sold 87,500 ARS Pharmaceuticals shares in Q1 2024, an estimated $480K.
Denali Advisors first reported a position in ARS Pharmaceuticals in Q4 2023 and held it in 1 quarter.
Denali Advisors's ARS Pharmaceuticals position peaked at $480K in Q4 2023.
113 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2024.

Based on Denali Advisors's 13F filing for Q1 2024, filed 19 Apr 2024.